Compare HRMY & DCO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | HRMY | DCO |
|---|---|---|
| Founded | 2017 | 1849 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Military/Government/Technical |
| Sector | Health Care | Industrials |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.6B | 1.9B |
| IPO Year | 2020 | 1995 |
| Metric | HRMY | DCO |
|---|---|---|
| Price | $32.44 | $136.91 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 9 | 5 |
| Target Price | $44.11 | ★ $153.60 |
| AVG Volume (30 Days) | ★ 799.5K | 191.9K |
| Earning Date | 05-07-2026 | 05-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 7.97 | N/A |
| EPS | ★ 2.71 | N/A |
| Revenue | ★ $868,453,000.00 | $824,730,000.00 |
| Revenue This Year | $19.75 | $7.40 |
| Revenue Next Year | $12.88 | $8.59 |
| P/E Ratio | $11.72 | ★ N/A |
| Revenue Growth | ★ 21.51 | 4.85 |
| 52 Week Low | $25.52 | $59.42 |
| 52 Week High | $40.87 | $145.90 |
| Indicator | HRMY | DCO |
|---|---|---|
| Relative Strength Index (RSI) | 66.25 | 49.96 |
| Support Level | $32.13 | $135.26 |
| Resistance Level | $33.21 | $143.08 |
| Average True Range (ATR) | 1.32 | 5.60 |
| MACD | 0.19 | -0.65 |
| Stochastic Oscillator | 58.88 | 10.94 |
Harmony Biosciences Holdings Inc is a commercial-stage pharmaceutical company focused on developing and commercializing therapies for patients living with rare neurological diseases who have unmet medical needs. The company has one reportable segment: rare neurological diseases. Its product WAKIX (pitolisant) is a molecule with a novel mechanism of action specifically designed to increase histamine signaling in the brain by binding to H3 receptors and is used for the treatment of cataplexy in adult patients with narcolepsy. The other drug candidates in its pipeline are Pitolisant, HBS-102 (MCHR1 antagonist), BP1.15205 (orexin-2 receptor agonist), ZYN002 (cannabidiol gel), EPX-100 (clemizole hydrochloride), and EPX-200 (lorcaserin), among others.
Ducommun Inc provides engineering & manufacturing services for high-performance products & high-cost-of failure applications used in the aerospace and defense, industrial, medical & other industries. The company's reportable segments are Structural Systems & Electronic Systems. Structural Systems designs, engineers and manufactures various sizes of complex contoured aerostructure components and assemblies and supplies composite and metal bonded structures and assemblies. Electronic Systems designs, engineers and manufactures high-reliability electronic and electromechanical products used in technology-driven markets including A&D and Industrial end-use markets. It generates maximum of its revenue from the Electronic Systems.